Stifel analyst Benjamin Burnett lowered the price target on CRISPR Therapeutics (NASDAQ: CRSP) to $64.00 (from $100.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE